Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_provenance.
- NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_assertion description "[Our results suggest that PSK may augment anti-tumour action via genes including multidrug resistance protein 3 (MRP3), lymphotactin (Lptn), transgelin (TAGLN), and Pirin, without disturbing cell-cycle progression, and may deserve a large clinical trial in cancer therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_provenance.
- NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_assertion evidence source_evidence_literature NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_provenance.
- NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_assertion SIO_000772 15547752 NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_provenance.
- NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_assertion wasDerivedFrom befree-20150227 NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_provenance.
- NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_assertion wasGeneratedBy ECO_0000203 NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_provenance.
- befree-20150227 importedOn "2015-02-27" NP722210.RABoSxPw6wvZ3pTECa6H_xgkEQPMforDtYzQ4tkFgC1Zo130_provenance.